John F Ward

List of Publications by Year
in descending order

115 papers	5,200 citations	126901 33 h-index	88628 70 g-index
120 all docs	120 docs citations	120 times ranked	5741 citing authors

#	Article	IF	Citations
1	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	30.7	467
2	Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostateâ€specific antigen testing: 15â€year outcome. BJU International, 2005, 95, 751-756.	2.5	417
3	The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy. Journal of Urology, 2003, 170, 1872-1876.	0.4	223
4	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology, 2020, 296, 76-84.	7.3	207
5	SALVAGE SURGERY FOR RADIORECURRENT PROSTATE CANCER: CONTEMPORARY OUTCOMES. Journal of Urology, 2005, 173, 1156-1160.	0.4	191
6	Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^{hi} T cell frequency and IFN-Î³ levels in both nonmalignant and malignant prostate tissues. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2729-2734.	7.1	183
7	Focal cryotherapy for localized prostate cancer: a report from the national Cryo Onâ€Line Database (COLD) Registry. BJU International, 2012, 109, 1648-1654.	2.5	181
8	Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. European Urology, 2014, 65, 1078-1083.	1.9	180
9	THE IMPACT OF SURGICAL APPROACH (NERVE BUNDLE PRESERVATION VERSUS WIDE LOCAL EXCISION) ON SURGICAL MARGINS AND BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2004, 172, 1328-1332.	0.4	153
10	Highâ€intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU International, 2009, 104, 1058-1062.	2.5	146
11	IMMEDIATE AND POSTOPERATIVE COMPLICATIONS OF TRANSURETHRAL PROSTATECTOMY IN THE 1990s. Journal of Urology, 1999, 162, 1307-1310.	0.4	136
12	Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging. European Urology, 2011, 59, 96-105.	1.9	127
13	Prospective Comparison of Computerized Tomography and Excretory Urography in the Initial Evaluation of Asymptomatic Microhematuria. Journal of Urology, 2002, 168, 2457-2460.	0.4	126
14	MULTI-INSTITUTIONAL EXPERIENCE WITH BUCCAL MUCOSA ONLAY URETHROPLASTY FOR BULBAR URETHRAL RECONSTRUCTION. Journal of Urology, 2002, 167, 1314-1317.	0.4	126
15	Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology, 2001, 58, 723-728.	1.0	122
16	PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study. Journal of Urology, 2013, 190, 64-69.	0.4	118
17	CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications, 2016, 7, 11674.	12.8	118
18	Locally Recurrent Prostate Cancer After Initial Radiation Therapy: A Comparison of Salvage Radical Prostatectomy Versus Cryotherapy. Journal of Urology, 2009, 182, 517-527.	0.4	116

#	Article	IF	Citations
19	Protease inhibitor-induced urolithiasis. Urology, 1997, 50, 508-511.	1.0	101
20	PROSTATE SPECIFIC ANTIGEN DOUBLING TIME SUBSEQUENT TO RADICAL PROSTATECTOMY AS A PROGNOSTICATOR OF OUTCOME FOLLOWING SALVAGE RADIOTHERAPY. Journal of Urology, 2004, 172, 2244-2248.	0.4	91
21	Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. European Urology, 2017, 71, 476-482.	1.9	85
22	Rising prostate-specific antigen after primary prostate cancer therapy. Nature Reviews Urology, 2005, 2, 174-182.	1.4	84
23	Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 117, 469-477.	2.5	81
24	Magnetic Resonance Guided, Focal Laser Induced Interstitial Thermal Therapy in a Canine Prostate Model. Journal of Urology, 2010, 184, 1514-1520.	0.4	73
25	Phase 1 prospective evaluation of the oncological adequacy of robotic assisted videoâ€endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU International, 2013, 111, 1068-1074.	2.5	66
26	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. European Urology, 2020, 78, 371-378.	1.9	66
27	Salvage highâ€intensity focused ultrasound (<scp>HIFU</scp>) for locally recurrent prostate cancer after failed radiation therapy: Multiâ€institutional analysis of 418 patients. BJU International, 2017, 119, 896-904.	2.5	61
28	Anatomy of the Lisfranc Ligament. Foot and Ankle Specialist, 2008, 1, 19-23.	1.0	52
29	Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU International, 2009, 104, 490-497.	2.5	50
30	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	4.1	39
31	Pathological Characteristics of Prostate Cancer Recurrence After Radiation Therapy: Implications for Focal Salvage Therapy. Journal of Urology, 2012, 188, 98-102.	0.4	37
32	Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer and Prostatic Diseases, 2018, 21, 524-532.	3.9	37
33	Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0â€“2) Tj ETQq1 1 0.784314 rgBT /O Oncology: Seminars and Original Investigations, 2004, 22, 40-47.	1.6	35
34	Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer*. Current Opinion in Urology, 2005, 15, 181-186.	1.8	33
35	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (SutentÂ®) a VEGFR2/PDGFRÎ²/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Journal of Hematology and Oncology, 2014, 7, 52.	17.0	33
36	Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World Journal of Urology, 2019, 37, 2147-2153.	2.2	32

#	Article	IF	Citations
37	Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. BJU International, 2011, 108, E196-E201.	2.5	31
38	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	2.5	27
39	The Influence of Pnx/Pn0 Grouping in a Multivariate Setting for Outcome Modeling in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2002, 168, 56-60.	0.4	25
40	Radical prostatectomy findings in patients predicted to have lowâ€volume/lowâ€grade prostate cancer diagnosed by extendedâ€core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU International, 2010, 105, 1386-1391.	2.5	25
41	Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU International, 2011, 108, 508-512.	2.5	25
42	Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. Prostate Cancer and Prostatic Diseases, 2012, 15, 256-259.	3.9	25
43	Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. European Urology Oncology, 2021, 4, 651-658.	5.4	25
44	Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget, 2016, 7, 86280-86289.	1.8	25
45	Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers, 2020, 12, 3755.	3.7	23
46	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	2.5	22
47	Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*. Current Opinion in Urology, 2005, 15, 187-195.	1.8	21
48	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	4.1	21
49	REFINED MICROSCOPIC URINALYSIS FOR RED BLOOD CELL MORPHOLOGY IN THE EVALUATION OF ASYMPTOMATIC MICROSCOPIC HEMATURIA IN A PEDIATRIC POPULATION. Journal of Urology, 1998, 160, 1492-1495.	0.4	19
50	Photoacoustic-based s O 2 estimation through excised bovine prostate tissue with interstitial light delivery. Photoacoustics, 2017, 7, 47-56.	7.8	19
51	Salvage Therapy for Radiorecurrent Prostate Cancer. Current Problems in Cancer, 2008, 32, 242-271.	2.0	18
52	Classification System: Organ Preserving Treatment for Prostate Cancer. Urology, 2010, 75, 1258-1260.	1.0	18
53	Cryoablation for locally advanced clinical stage <scp>T</scp>3 prostate cancer: a report from the <scp>C</scp>ryoâ€<scp>O</scp>nâ€<scp>L</scp>ine <scp>D</scp>atabase (<scp>COLD</scp>) <scp>R</scp>egistry. BJU International, 2014, 113, 714-718.	2.5	18
54	Expanding the differential diagnosis of the acute scrotum: ventriculoperitoneal shunt herniation. Urology, 2001, 58, 281.	1.0	17

#	Article	IF	Citations
55	Radical prostatectomy for the patient with locally advanced prostate cancer. Current Urology Reports, 2003, 4, 196-204.	2.2	16
56	Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts (â€œICEâ€). Aging Male, 2014, 17, 66-71.	1.9	16
57	Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e1-495.e7.	1.6	16
58	Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. European Urology, 2018, 74, 140-143.	1.9	16
59	THE ULTRASONIC DESCRIPTION OF POSTPUBERTAL TESTICLES IN MEN WHO HAVE UNDERGONE PREPUBERTAL ORCHIOPEXY FOR CRYPTORCHIDISM. Journal of Urology, 2000, 163, 1448-1450.	0.4	14
60	Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clinical Genitourinary Cancer, 2016, 14, 130-138.	1.9	14
61	Simplified lipid II-binding antimicrobial peptides: Design, synthesis and antimicrobial activity of bioconjugates of nisin rings A and B with pore-forming peptides. Bioorganic and Medicinal Chemistry, 2018, 26, 5691-5700.	3.0	14
62	Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Canadian Journal of Urology, 2016, 23, 8271-7.	0.0	14
63	High-Intensity Focused Ultrasound for Therapeutic Tissue Ablation in Surgical Oncology. Surgical Oncology Clinics of North America, 2011, 20, 389-407.	1.5	13
64	Focal therapy for the treatment of localized prostate cancer. Current Opinion in Urology, 2012, 22, 104-108.	1.8	12
65	Comparing confirmatory biopsy outcomes between MRIâ€targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU International, 2021, 127, 340-348.	2.5	12
66	Malignant Cytological Washings from Radical Prostatectomy Specimens: A Possible Mechanism for Local Recurrence of Prostate Cancer Following Surgical Treatment of Organ Confined Disease. Journal of Urology, 1996, 156, 1381-1385.	0.4	11
67	MALIGNANT CYTOLOGICAL WASHINGS FROM PROSTATE SPECIMENS: : AN INDEPENDENT PREDICTOR OF BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2001, 165, 469-473.	0.4	10
68	Baseline and longitudinal plasma caveolinâ€1 level as a biomarker in active surveillance for earlyâ€stage prostate cancer. BJU International, 2018, 121, 69-76.	2.5	10
69	Considerations for patient selection for focal therapy. Therapeutic Advances in Urology, 2013, 5, 330-337.	2.0	9
70	Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 276-280.	3.9	9
71	Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters. European Urology Open Science, 2021, 27, 53-60.	0.4	9
72	HEMANGIOMA PRESENTING AS AN ULCERATION OF THE SCROTUM. Journal of Urology, 1998, 160, 182-183.	0.4	8

#	Article	IF	Citations
73	Treating the Biochemical Recurrence of Prostate Cancer After Definitive Primary Therapy. Clinical Prostate Cancer, 2005, 4, 38-44.	2.1	8
74	Comparative Effectiveness, Cost, and Utilization of Radical Prostatectomy among Young Men within Managed Care Insurance Plans. Value in Health, 2012, 15, 367-375.	0.3	8
75	Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers, 2022, 14, 1127.	3.7	8
76	Contemporary outcomes of focal therapy in prostate cancer: what do we know so farâ€¦. World Journal of Urology, 2010, 28, 593-597.	2.2	7
77	Is transureteroureterostomy performed during multiâ€organ resection for nonâ€urothelial malignancy safe and effective?. Journal of Surgical Oncology, 2012, 106, 62-65.	1.7	7
78	Health technology assessment in evolution â€“ focal therapy in localised prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 1359-1367.	2.4	7
79	Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer, 2021, 127, 720-728.	4.1	7
80	Making a case â€œforâ€•focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials. World Journal of Urology, 2021, 39, 729-739.	2.2	7
81	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	6.1	6
82	Detection and Treatment of Primary Prostatic Melanoma. Urology, 2019, 123, 16-19.	1.0	6
83	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology, 2020, 138, 91-97.	1.0	6
84	SYNCOPE FROM INCREASED VENTRICULAR RESPONSE IN ATRIAL FIBRILLATION DURING VOIDING: A NEW INDICATION FOR SURGICAL MANAGEMENT IN BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 1999, 161, 606-607.	0.4	5
85	The Effects of Dietary Factors on the Androgen Receptor and Related Cellular Factors in Prostate Cancer. Current Medicinal Chemistry, 2004, 11, 909-923.	2.4	5
86	Management of the Patient with a Rising PSA Alone. Hematology/Oncology Clinics of North America, 2006, 20, 897-908.	2.2	5
87	The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World Journal of Surgical Oncology, 2015, 13, 340.	1.9	5
88	Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer, 2020, 126, 4878-4885.	4.1	5
89	Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World Journal of Urology, 2021, 39, 3259-3264.	2.2	5
90	The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. Journal of Urology, 2002, 168, 56-60.	0.4	5

#	Article	IF	Citations
91	Editorial Comment on: Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy. European Urology, 2010, 57, 444-445.	1.9	4
92	Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 993-998.	4.9	4
93	Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes. Canadian Urological Association Journal, 2017, 11, E277-84.	0.6	4
94	Active surveillance monitoring: the role of novel biomarkers and imaging. Asian Journal of Andrology, 2015, 17, 882.	1.6	4
95	Multiple Kinase Pathways Involved in the Different De Novo Sensitivity ofÂPancreatic Cancer Cell Lines to 17-AAG. Journal of Surgical Research, 2012, 176, 147-153.	1.6	2
96	Characterization of Glomus Tumors of the Kidney. Clinical Genitourinary Cancer, 2018, 16, e253-e256.	1.9	2
97	Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy. BJU International, 2021, 127, 524-527.	2.5	2
98	Impact of MRI/US fusionâ€guided prostate biopsy on biopsyâ€naÃ¯ve patients: A single urologistâ€™s experience. BJUI Compass, 2022, 3, 19-25.	1.3	2
99	Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. Journal of Urology, 2021, 206, 646-654.	0.4	2
100	Free-to-total prostate-specific antigen ratios 18-24 months following external beam radiation for adenocarcinoma of the prostate. , 1999, 70, 91-94.		1
101	HIFU is effective, but associated morbidity still remains unclear. Nature Reviews Urology, 2010, 7, 597-598.	3.8	1
102	Re: Jan P. Radtke, Constantin Schwab, Maya B. Wolf, et al. Multiparametric Magnetic Resonance Imaging (MRI) and MRIâ€“Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.12.052. European Urology, 2016, 70, e77-e78.	1.9	1
103	Paratesticular clear cell carcinoma of mÃ¼llerian originâ€”A case report. Human Pathology: Case Reports, 2020, 21, 200401.	0.2	1
104	Predictive capacity of a miRNA panel in identifying teratoma in postâ€chemotherapy consolidation surgeries. BJUI Compass, 2023, 4, 81-87.	1.3	1
105	THE EFFECT OF FRESH HUMAN BLOOD SERUM ON ARTIFICIAL MEDIA.. Lancet, The, 1916, 188, 692-693.	13.7	0
106	THE INTRAVENOUS INJECTION OF QUININE.. Lancet, The, 1917, 189, 428.	13.7	0
107	MANGANESE POISONING.. Lancet, The, 1918, 192, 474.	13.7	0
108	Radical prostatectomy for the patient with locally advanced prostate cancer. Current Prostate Reports, 2003, 1, 5-13.	0.1	0

#	Article	IF	Citations
109	Atlas of Genitourinary OncologyMovsasB., HudesG. and OlssonC.: Atlas of Genitourinary Oncology. In: . Philadelphia: W. B. Saunders2002: 221 pages.. Journal of Urology, 2003, 169, 1203-1203.	0.4	0
110	Chemoprevention of prostate cancer. Expert Review of Anticancer Therapy, 2003, 3, 203-214.	2.4	0
111	Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?. Nature Reviews Urology, 2006, 3, 310-311.	1.4	0
112	Survey of EndourologyHoward N. Winfield, M.D., Section Editor. Journal of Endourology, 2012, 26, 90-101.	2.1	0
113	Prostate Focal Therapy: Definitions and Common Terminology. , 2013, , 237-244.		0
114	Prostate Focal Therapy: Definitions and Common Terminology. Current Clinical Urology, 2017, , 139-144.	0.0	0
115	Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU International, 2021, , .	2.5	0